1. The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7–H4 in lung adenocarcinoma harboring EGFR-activating mutants.
- Author
-
Lu, Youwei, Sun, Yu, Zhang, Jie, Kong, Miao, Zhao, Zhiming, Sun, Boshu, Wang, Yuan, Jiang, Ying, Chen, Shaomu, Wang, Chao, Tong, Yin, Wen, Liangzhu, Huang, Moli, Wu, Fengying, and Zhang, Liang
- Subjects
- *
IMMUNE checkpoint proteins , *IMMUNOSUPPRESSION , *CARRIER proteins , *LUNGS , *TUMOR growth - Abstract
B7–H4 is an immune checkpoint crucial for inhibiting CD8+ T-cell activity. A clinical trial is underway to investigate B7–H4 as a potential immunotherapeutic agent. However, the regulatory mechanism of B7–H4 degradation via the ubiquitin-proteasome pathway (UPP) remains poorly understood. In this study, we discovered that proteasome inhibitors effectively increased B7–H4 expression, while EGFR-activating mutants promoted B7–H4 expression through the UPP. We screened B7–H4 binding proteins by co-immunoprecipitation and mass spectrometry and found that USP2a acted as a deubiquitinase of B7–H4 by removing K48- and K63-linked ubiquitin chains from B7–H4, leading to a reduction in B7–H4 degradation. EGFR mutants enhanced B7–H4 stability by upregulating USP2a expression. We further investigated the role of USP2a in tumor growth in vivo. Depletion of USP2a in L858R/LLC cells inhibited tumor cell proliferation, consequently suppressing tumor growth in immune-deficient nude mice by destabilizing downstream molecules such as Cyclin D1. In an immune-competent C57BL/6 mouse tumor model, USP2a abrogation facilitated infiltration of CD95+CD8+ effector T cells and hindered infiltration of Tim-3+CD8+ and LAG-3+CD8+ exhausted T cells by destabilizing B7–H4. Clinical lung adenocarcinoma samples showed a significant correlation between B7–H4 abundance and USP2a expression, indicating the contribution of the EGFR/USP2a/B7–H4 axis to tumor immunosuppression. In summary, this study elucidates the dual effects of USP2a in tumor growth by stabilizing Cyclin D1, promoting tumor cell proliferation, and stabilizing B7–H4, contributing to tumor immunosuppression. Therefore, USP2a represents a potential target for tumor therapy. • EGFR activating mutants promote B7–H4 stability through ubiquitin-proteosome pathway. • Deubiquitinase USP2a interacts with B7–H4 and mediates EGFR MT-inducing B7–H4 stability. • USP2a is upregulated in lung adenocarcinoma harboring EGFR mutants. • EGFR/USP2a/B7–H4 axis contributes to tumor immunosuppression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF